Capacity Bio
Focus: Capacity Bio is an early-stage biotechnology company focused on mitophagy-based therapeutics for oncology. The company is pre-revenue with minimal public visibility and no disclosed funding or employee count.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Total Funding
$35M
Open Jobs
0
About Capacity Bio
AI assessmentNot HiringNo open roles listed right now. Follow Capacity Bio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
0/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Open Jobs (0)
No open positions listed yet.
Interview Prep Quick Facts
H-1B (2023): 1 approval
Visa Sponsorship
Sponsors Work Visas
Help build intelligence for Capacity Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.